Orin Green Financial LLC Sells 22,000 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Orin Green Financial LLC lessened its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) by 30.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the company’s stock after selling 22,000 shares during the quarter. Orin Green Financial LLC owned about 0.06% of Protalix BioTherapeutics worth $128,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Stratos Wealth Partners LTD. boosted its position in shares of Protalix BioTherapeutics by 28.3% during the 1st quarter. Stratos Wealth Partners LTD. now owns 346,400 shares of the company’s stock worth $887,000 after purchasing an additional 76,400 shares in the last quarter. Squarepoint Ops LLC raised its holdings in shares of Protalix BioTherapeutics by 33.4% in the 4th quarter. Squarepoint Ops LLC now owns 73,940 shares of the company’s stock worth $139,000 after acquiring an additional 18,522 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Protalix BioTherapeutics by 13.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company’s stock worth $101,000 after acquiring an additional 6,434 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Protalix BioTherapeutics by 3.8% in the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock worth $729,000 after acquiring an additional 14,164 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock worth $55,000 after acquiring an additional 5,686 shares during the last quarter. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Price Performance

PLX opened at $1.55 on Friday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $3.10. The firm has a market capitalization of $123.39 million, a PE ratio of -11.92 and a beta of -0.23. The company’s 50-day moving average is $1.52 and its 200 day moving average is $2.12.

Protalix BioTherapeutics (NYSE:PLX) last posted its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. As a group, analysts expect that Protalix BioTherapeutics, Inc. will post 0.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, May 12th.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.